研究报告

双定位信号增强工程化蛋白线粒体靶向性呈递

展开
  • 1.西北农林科技大学动物科技学院,杨凌 712100
    2.空军军医大学肿瘤生物学国家重点实验室,西安 710000
周冰倩,本科,专业方向:动物科学。E-mail: 2770998747@qq.com
邢金良,博士,教授,研究方向:线粒体生物学与肿瘤防治。E-mail: xingjl@fmmu.edu.cn;
徐坤,博士,副教授,研究方向:基因编辑工具的开发及研究应用。E-mail: xukun@nwafu.edu.cn

收稿日期: 2024-06-12

  修回日期: 2024-09-01

  网络出版日期: 2024-09-04

基金资助

农业生物育种重大专项(2023ZD04074);农业生物育种重大专项(2023ZD04051);肿瘤生物学国家重点实验室开放基金(CBSKL2022ZDKF11)

Dual-localization signals enhance mitochondrial targeted presentation of engineered proteins

Expand
  • 1. College of Animal Science and Technology, Northwest A&F University, Yangling 71200, China
    2. State Key Laboratory of Tumour Biology, Fourth Military Medical University, Xi'an 710000, China

Received date: 2024-06-12

  Revised date: 2024-09-01

  Online published: 2024-09-04

Supported by

Biological Breeding-Major Projects(2023ZD04074);Biological Breeding-Major Projects(2023ZD04051);Open Fund Project from State Key Laboratory of Tumor Biology-China(CBSKL2022ZDKF11)

摘要

有效传递工程化改造的蛋白进入线粒体对开发高效的线粒体DNA编辑工具、实现线粒体疾病精准治疗具有重要意义。本研究选取eGFPCas9基因,在其上游或/和下游引入不同的线粒体定位信号(mitochondrial localization signal,MLS)序列,分别构建了相应的工程化蛋白表达载体。将不同表达载体转染HEK293T细胞后,利用荧光共定位实验和免疫印迹实验分析不同工程化蛋白的线粒体靶向性呈递效果。结果显示,相比单端添加MLS的eGFP和Cas9蛋白,双端MLS改造均显著提高了工程化蛋白的线粒体靶向性呈递效率。推测双MLS策略可增强工程化蛋白的线粒体靶向性,为以后开发高效的线粒体DNA编辑工具奠定了理论基础。

本文引用格式

周冰倩, 李尚朴, 王旭, 孟祥宇, 邓竞荣, 邢金良, 王建刚, 徐坤 . 双定位信号增强工程化蛋白线粒体靶向性呈递[J]. 遗传, 2024 , 46(11) : 937 -946 . DOI: 10.16288/j.yczz.24-171

Abstract

Effective delivery of engineered proteins into mitochondria is of great significance for developing efficient mitochondrial DNA editing tools and realizing accurate treatment of mitochondrial diseases. Here, the candidate genes, eGFP and Cas9, were engineered with different mitochondrial localization signal (MLS) sequences introduced at their up- or/and down-streams. The corresponding expression vectors for the engineered proteins were constructed respectively, and HEK293T cells were transfected with these vectors. The fluorescence colocalization and Western blotting assays were used to analyze the mitochondrial targeting presentation effect of different engineered proteins. The results demonstrated that the daul-MLS modification of the eGFP and Cas9 proteins significantly improved the efficiency of mitochondrial targeted presentation, compared with the engineered proteins with single MLS added. Hence, it is speculated that dual MLS strategy can enhance the mitochondrial targeting of engineered proteins, which lays a theoretical foundation for the future development of efficient mitochondrial DNA editing tools.

参考文献

[1] Mcbride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol, 2006, 16(14): R551- R560.
[2] Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG. Sequence and organization of the human mitochondrial genome. Nature, 1981, 290(5806): 457-465.
[3] Falkenberg M. Mitochondrial DNA replication in mammalian cells: overview of the pathway. Essays Biochem, 2018, 62(3): 287-296.
[4] Stewart JB, Chinnery PF. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat Rev Genet, 2015, 16(9): 530-542.
[5] Chinnery PF, Thorburn DR, Samuels DC, White SL, Dahl HM, Turnbull DM, Lightowlers RN, Howell N. The inheritance of mitochondrial DNA heteroplasmy: random drift, selection or both? Trends Genet, 2000, 16(11): 500-505.
[6] Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Feeney C, Horvath R, Yu-Wai-Man P, Chinnery PF, Taylor RW, Turnbull DM, Mcfarland R. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol, 2015, 77(5): 753-759.
[7] Gorman GS, Chinnery PF, Dimauro S, Hirano M, Koga Y, Mcfarland R, Suomalainen A, Thorburn DR, Zeviani M, Turnbull DM. Mitochondrial diseases. Nat Rev Dis Primers, 2016, 2: 16080.
[8] Nissanka N, Moraes CT. Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches. EMBO Rep, 2020, 21(3): e49612.
[9] Hyslop LA, Blakeley P, Craven L, Richardson J, Fogarty NME, Fragouli E, Lamb M, Wamaitha SE, Prathalingam N, Zhang Q, O'Keefe H, Takeda Y, Arizzi L, Alfarawati S, Tuppen HA, Irving L, Kalleas D, Choudhary M, Wells D, Murdoch AP, Turnbull DM, Niakan KK, Herbert M. Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. Nature, 2016, 534(7607): 383-386.
[10] Tachibana M, Sparman M, Sritanaudomchai H, Ma H, Clepper L, Woodward J, Li Y, Ramsey C, Kolotushkina O, Mitalipov S. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature, 2009, 461(7262): 367-372.
[11] Srivastava S, Moraes CT. Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. Hum Mol Genet, 2001, 10(26): 3093-3099.
[12] Minczuk M, Papworth MA, Miller JC, Murphy MP, Klug A. Development of a single-chain, quasi-dimeric zinc- finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucleic Acids Res, 2008, 36(12): 3926-3938.
[13] Bacman SR, Williams SL, Pinto M, Peralta S, Moraes CT. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat Med, 2013, 19(9): 1111-1113.
[14] Reddy P, Ocampo A, Suzuki K, Luo JP, Bacman SR, Williams SL, Sugawara A, Okamura D, Tsunekawa Y, Wu J, Lam D, Xiong X, Montserrat N, Esteban CR, Liu GH, Sancho-Martinez I, Manau D, Civico S, Cardellach F, Del Mar O'Callaghan M, Campistol J, Zhao HM, Campistol JM, Moraes CT, Izpisua BJ. Selective elimination of mitochondrial mutations in the germline by genome editing. Cell, 2015, 161(3): 459-469.
[15] Gammage PA, Gaude E, Van Haute L, Rebelo-Guiomar P, Jackson CB, Rorbach J, Pekalski ML, Robinson AJ, Charpentier M, Concordet JP, Frezza C, Minczuk M. Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs. Nucleic Acids Res, 2016, 44(16): 7804-7816.
[16] Owen RT, Flotte TR. Approaches and limitations to gene therapy for mitochondrial diseases. Antioxid Redox Signal, 2001, 3(3): 451-460.
[17] Zhang F, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol, 2011, 29(2): 149-153.
[18] Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, Hsu F, Radey MC, Peterson SB, Mootha VK, Mougous JD, Liu DR. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature, 2020, 583(7817): 631-637.
[19] Cho SI, Lee S, Mok YG, Lim K, Lee J, Lee JM, Chung E, Kim JS. Targeted A-to-G base editing in human mitochondrial DNA with programmable deaminases. Cell, 2022, 185(10): 1764-1776.e12.
[20] Wei YH, Li ZF, Xu K, Feng H, Xie L, Li D, Zuo ZR, Zhang ML, Xu CL, Yang H, Zuo EW. Mitochondrial base editor DdCBE causes substantial DNA off-target editing in nuclear genome of embryos. Cell Discov, 2022, 8(1): 27.
[21] Lei ZX, Meng HW, Liu LL, Zhao HN, Rao XC, Yan YC, Wu H, Liu M, He AB, Yi CQ. Mitochondrial base editor induces substantial nuclear off-target mutations. Nature, 2022, 606(7915): 804-811.
[22] Mok BY, Kotrys AV, Raguram A, Huang TP, Mootha VK, Liu DR. CRISPR-free base editors with enhanced activity and expanded targeting scope in mitochondrial and nuclear DNA. Nat Biotechnol, 2022, 40(9): 1378-1387.
[23] Mi L, Shi M, Li YX, Xie G, Rao XC, Wu DM, Cheng AM, Niu MX, Xu FL, Yu Y, Gao N, Wei WS, Wang XH, Wang YM. DddA homolog search and engineering expand sequence compatibility of mitochondrial base editing. Nat Commun, 2023, 14(1): 874.
[24] Wei YH, Xu CL, Feng H, Xu K, Li ZF, Hu J, Zhou L, Wei Y, Zuo ZR, Zuo EW, Li W, Yang H, Zhang ML. Human cleaving embryos enable efficient mitochondrial base-editing with DdCBE. Cell Discov, 2022, 8(1): 7.
[25] Chen XX, Liang D, Guo JY, Zhang JQ, Sun HF, Zhang XL, Jin JC, Dai YC, Bao QM, Qian XZ, Tan L, Hu P, Ling XF, Shen B, Xu ZF. DdCBE-mediated mitochondrial base editing in human 3PN embryos. Cell Discov, 2022, 8(1): 8.
[26] Wang B, Lv XJ, Wang YF, Wang ZB, Liu Q, Lu B, Liu Y, Gu F. CRISPR/Cas9-mediated mutagenesis at microhomologous regions of human mitochondrial genome. Sci China Life Sci, 2021, 64(9): 1463-1472.
[27] Bi R, Li Y, Xu M, Zheng QZ, Zhang DF, Li X, Ma GL, Xiang BL, Zhu XJ, Zhao H, Huang XX, Zheng P, Yao YG. Direct evidence of CRISPR-Cas9-mediated mitochondrial genome editing. Innovation (Camb), 2022, 3(6): 100329.
[28] Yi ZY, Zhang XX, Tang W, Yu Y, Wei XX, Zhang X, Wei WS. Strand-selective base editing of human mitochondrial DNA using mitoBEs. Nat Biotechnol, 2023, 42(3): 498-509.
文章导航

/